RNA Targeting Small Molecules Therapeutics Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033

The rna targeting small molecules therapeutics market size has grown exponentially in recent years. It will grow from $1.06 billion in 2023 to $1.45 billion in 2024 at a compound annual growth rate (CAGR) of 37.0%. The growth in the historic period can be attributed to drug discovery and development, rising prevalence of rna-related diseases, government and private funding, pharmaceutical industry interest, rna therapeutics success stories.

The rna targeting small molecules therapeutics market size is expected to see exponential growth in the next few years. It will grow to $5.09 billion in 2028 at a compound annual growth rate (CAGR) of 36.9%. The growth in the forecast period can be attributed to precision medicine and personalized therapies, rise in rna biomarker identification, expanding rna target spectrum, increasing funding and investments, application in rare diseases. Major trends in the forecast period include advancements in screening technologies, antisense oligonucleotides dominance, small molecule rna binders, rna therapeutics in neurological disorders, gene editing with crispr-cas9.

Market Overview -
RNA-targeting small molecule therapeutics refers to small molecule therapeutics that precisely interact with RNA molecules to modify their function or stability. These treatments treat diseases by employing small-molecule drugs to target disease-causing RNA molecules.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

Surge In Cancer Cases Fuels Expansion Of The Rna-Targeting Small Molecule Therapeutics Market
The increasing number of cancer cases is expected to propel the growth of the RNA-targeting small molecule therapeutics market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Cancer is treated with RNA-targeting small molecules created and investigated to target RNA molecules associated with cancer selectively. For instance, in January 2022, according to research published by the American Cancer Society, a US-based health organization, in the US, 609,360 cancer deaths and 1.9 million new cancer cases are anticipated in 2022. It is about 1,670 fatalities each day. Therefore, the increasing number of cancer cases is driving the growth of the RNA-targeting small molecule therapeutics market.

Competitive Landscape -
Major companies operating in the rna targeting small molecules therapeutics market report are F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Celgene Corporation, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics.

Strategic Partnerships Drive Innovation In The Rna-Targeting Small Molecule Therapeutics Market
Strategic partnerships are a key trend gaining popularity in the RNA-targeting small molecule therapeutics market. Major companies operating in the RNA-targeting small molecule therapeutics market are undergoing partnerships to develop a new relationship in which two or more organizations develop innovative products. For instance, in June 2022, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical manufacturing company, collaborated with xFOREST Therapeutics Co. Ltd., a Japan-based developer of drug discovery platforms. With this partnership, xFOREST will offer Otsuka with its Forest technology to advance systemic small-molecule drug discovery research focusing on RNA structures. Furthermore, in March 2021, Evotec SE, a Germany-based drug discovery and development company, entered a strategic alliance with Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company. Both companies aim to discover and develop RNA-targeting small molecules with this alliance.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Key Segments -

The rna targeting small molecules therapeutics market covered in this report is segmented -

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings
2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications
3) By Application: Drug Discovery, Oncology Research, Disease Identification
4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.